Evonik launches scientifically proven synbiotic solutions IN VIVO BIOTICS™

* Meets customer demand for science-based synbiotic solutions
* Unique insights support fast-market approach
* Superior expertise in biotechnology and formulation

**Essen, Germany**. Evonik has launched a new category of nutraceuticals called IN VIVO BIOTICS™. These next-generation synbiotics combine probiotics – healthy gut bacteria – with other health ingredients. IN VIVO BIOTICS™ are based on scientific understanding of human health with deep knowledge of the market for food ingredients and dietary supplements. Customers working on innovative nutraceuticals and health solutions benefit from Evonik’s superior expertise in biotechnology and formulation, as well as reliable delivery, excellent quality standards and scalable production.

“We believe the human microbiome has great potential for maintaining good health. That’s why we are thrilled to offer our customers science-based nutraceutical solutions like IN VIVO BIOTICS™,” said Maximillian Yeh, head of Health Solutions at

Evonik’s Health Care business.

Evonik offers nutraceutical companies a range of IN VIVO

BIOTICS™ solutions such as IN VIVO BIOTICS™ butyrate that

supports intrinsic butyrate production, IN VIVO BIOTICS™ resolvin and IN VIVO BIOTICS™ gluten tolerance. Customers also benefit

from Evonik’s offering of unique insights for a fast-market approach by supporting consumer translation, product positioning, consumer awareness and packaging design.

IN VIVO BIOTICS™ is part of a nutraceuticals portfolio of advanced health ingredients, coatings, formulation services and finished dosage forms offered by Evonik’s Health Care business. The Health Care business at Evonik is part of the company’s life sciences division, Nutrition & Care, which aims to increase its share of System Solutions from 20 percent today to more than 50

24 January 2023

**Main press contact Julia Born**

Head of Market Communications Health Care

Phone +49 6151 18-4984

[julia1.born@evonik.com](mailto:julia1.born@evonik.com)

**Alternative press contact Dr. Jürgen Krauter**

Head of Market Communications Evonik Phone +49 6181 59-6847

[juergen.krauter@evonik.com](mailto:juergen.krauter@evonik.com)

**Evonik Industries AG** Rellinghauser Straße 1-11

45128 Essen Germany

Phone +49 201 177-01

[www.evonik.com](http://www.evonik.com/)

Supervisory Board Bernd Tönjes, Chairman Executive Board

Christian Kullmann, Chairman

Dr. Harald Schwager, Deputy Chairman Thomas Wessel, Ute Wolf

Registered Office is Essen Register Court Essen Local Court Commercial Registry B 19474

percent by 2030. System Solutions are defined as multicomponent systems tailored to a specific customer need.

**More Information**

[https://healthcare.evonik.com/en/nutrition/health-](https://healthcare.evonik.com/en/nutrition/health-ingredients/synbiotics) [ingredients/synbiotics](https://healthcare.evonik.com/en/nutrition/health-ingredients/synbiotics)

**Company information**

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.38 billion in 2021. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

**About Nutrition & Care**

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.56 billion in 2021 with about 5,300 employees.

**Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment.

Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.